KR102240999B1 - 피페리디늄 4급 염들 - Google Patents

피페리디늄 4급 염들 Download PDF

Info

Publication number
KR102240999B1
KR102240999B1 KR1020207005139A KR20207005139A KR102240999B1 KR 102240999 B1 KR102240999 B1 KR 102240999B1 KR 1020207005139 A KR1020207005139 A KR 1020207005139A KR 20207005139 A KR20207005139 A KR 20207005139A KR 102240999 B1 KR102240999 B1 KR 102240999B1
Authority
KR
South Korea
Prior art keywords
methyl
alkyl
diphenyl
piperidinium
acetoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020207005139A
Other languages
English (en)
Korean (ko)
Other versions
KR20200022522A (ko
Inventor
캐슬린 이. 클라렌스-스미스
토마스 엔. 체이스
Original Assignee
체이스 파마슈티칼스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 체이스 파마슈티칼스 코포레이션 filed Critical 체이스 파마슈티칼스 코포레이션
Publication of KR20200022522A publication Critical patent/KR20200022522A/ko
Application granted granted Critical
Publication of KR102240999B1 publication Critical patent/KR102240999B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
KR1020207005139A 2012-08-09 2013-07-30 피페리디늄 4급 염들 Expired - Fee Related KR102240999B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261681415P 2012-08-09 2012-08-09
US61/681,415 2012-08-09
PCT/US2013/052626 WO2014025569A1 (en) 2012-08-09 2013-07-30 Piperidinium quaternary salts

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR20157006047A Division KR20150040355A (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들

Publications (2)

Publication Number Publication Date
KR20200022522A KR20200022522A (ko) 2020-03-03
KR102240999B1 true KR102240999B1 (ko) 2021-04-15

Family

ID=50068488

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207005139A Expired - Fee Related KR102240999B1 (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들
KR20157006047A Ceased KR20150040355A (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR20157006047A Ceased KR20150040355A (ko) 2012-08-09 2013-07-30 피페리디늄 4급 염들

Country Status (14)

Country Link
US (1) US9896416B2 (enExample)
EP (1) EP2882711B1 (enExample)
JP (1) JP6345665B2 (enExample)
KR (2) KR102240999B1 (enExample)
CN (2) CN108658842A (enExample)
AU (1) AU2013300009B2 (enExample)
BR (1) BR112015002832B1 (enExample)
CA (1) CA2881182C (enExample)
EA (1) EA029678B9 (enExample)
HK (1) HK1211572A1 (enExample)
IL (1) IL236996A0 (enExample)
IN (1) IN2015DN01018A (enExample)
MX (1) MX356386B (enExample)
WO (1) WO2014025569A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144719A1 (en) 2015-03-06 2016-09-15 Chase Thomas N Oxybutynin transdermal therapeutic system muscarinic agonist combination
US20180360845A1 (en) * 2015-07-20 2018-12-20 Chase Pharmaceuticals Corporation Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders
CN114868435B (zh) 2019-08-22 2023-12-26 欧芬诺有限责任公司 针对多址接入的策略控制
CN117018194A (zh) * 2023-07-26 2023-11-10 同济大学 毒蕈碱型受体5型受体拮抗剂的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD106643A1 (enExample) 1973-07-12 1974-06-20
CN1285348A (zh) 1999-08-20 2001-02-28 广东康美药业股份有限公司 盐酸丙哌维林合成工艺
DE10129832A1 (de) * 2001-06-17 2003-07-10 Berolina Drug Dev Ab Svedala Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
KR100500760B1 (ko) 2003-07-22 2005-07-14 동방에프티엘 주식회사 염산 프로피베린의 제조방법
KR100510788B1 (ko) 2003-07-22 2005-08-26 동방에프티엘 주식회사 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법
NZ548300A (en) * 2004-02-06 2010-04-30 Meda Pharma Gmbh & Co Kg The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and COPD
EP1921989A2 (en) * 2005-08-12 2008-05-21 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Neuronal avalanche assay
CN1951938A (zh) * 2005-10-21 2007-04-25 刘丽娅 戊乙奎醚季铵盐及其衍生物
SE0600876L (sv) 2006-04-20 2007-10-21 Sandvik Intellectual Property Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form
CN101490003A (zh) * 2006-04-24 2009-07-22 阿斯利康(瑞典)有限公司 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物
WO2007123465A1 (en) * 2006-04-24 2007-11-01 Astrazeneca Ab New alkyl esters of cyclic amino alcohols with muscarinic m3 receptor antagonist activity, useful for treating e.g. chronic bronchial obstruction, asthma and overactive bladder
JP2012530050A (ja) * 2010-03-15 2012-11-29 ラマクリシュナ、ラメシャ アンダガル 塩酸プロピベリンの合成
KR101149821B1 (ko) 2010-04-05 2012-05-24 하나제약 주식회사 디페닐아세테이트 유도체의 새로운 제조방법
CN102218063B (zh) 2011-04-12 2013-03-13 贵州神奇制药有限公司 盐酸丙哌维林药物的制备方法和产品及其检测方法
MX378091B (es) * 2012-09-05 2025-03-10 Chase Pharmaceuticals Corp Composicion neuroprotectora anticolinergica y metodos.

Also Published As

Publication number Publication date
KR20200022522A (ko) 2020-03-03
CN104603108A (zh) 2015-05-06
EA201500209A1 (ru) 2015-05-29
JP2015524469A (ja) 2015-08-24
HK1211572A1 (en) 2016-05-27
CA2881182C (en) 2021-01-26
IL236996A0 (en) 2015-03-31
WO2014025569A1 (en) 2014-02-13
EA029678B9 (ru) 2018-07-31
BR112015002832B1 (pt) 2022-08-16
CA2881182A1 (en) 2014-02-13
EP2882711B1 (en) 2017-10-25
KR20150040355A (ko) 2015-04-14
EA029678B1 (ru) 2018-04-30
AU2013300009A1 (en) 2015-02-26
IN2015DN01018A (enExample) 2015-06-26
JP6345665B2 (ja) 2018-06-20
US9896416B2 (en) 2018-02-20
US20150203452A1 (en) 2015-07-23
BR112015002832A2 (enExample) 2017-07-04
EP2882711A4 (en) 2016-02-10
MX2015001769A (es) 2015-05-08
EP2882711A1 (en) 2015-06-17
AU2013300009B2 (en) 2017-06-15
CN108658842A (zh) 2018-10-16
MX356386B (es) 2018-05-28

Similar Documents

Publication Publication Date Title
RU2193557C2 (ru) Бензоциклогептатиофеновые соединения, способы профилактики или лечения, фармацевтическая композиция
CN105481796B (zh) 一类氨基甲酸查尔酮酯类化合物、其制备方法和用途
JPH06506473A (ja) 窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
TW200306830A (en) N-[phenyl (piperidin-2-yl) methyl] benzamide derivatives, their preparation and their application in therapy
KR102240999B1 (ko) 피페리디늄 4급 염들
WO2023087611A1 (zh) 一类依巴斯汀的盐及其制备方法和应用
TW200526573A (en) Organic compounds
JP2001506601A (ja) α―２アドレナリン受容体作動薬として有用な２―イミダゾリニルアミノベンゾオキサゾール化合物
JPH09510222A (ja) ２，３，４，５−テトラヒドロ−１ｈ−３−ベンゾアゼピン化合物の酸付加塩
WO2014063587A1 (zh) 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
US20100204275A1 (en) N-piperidin-4-ylmethyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CN103006648A (zh) 一种马来酸左旋氨氯地平药物活性组合物及其制备方法
CN114805263A (zh) 3-(羟基苄基)苯酞类化合物、其制备方法和用途
CA2895968C (en) Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor
CN110698411A (zh) 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
CN105111195A (zh) 他克林-联苯双酯杂合物、其制备方法及应用
TW200836732A (en) Novel compounds
KR102399374B1 (ko) 알츠하이머병의 치료를 위한 ｎ-[2-(6-플루오로-1ｈ-인돌-3-일)에틸]-3-(2,2,3,3-테트라플루오로프로폭시)벤질아민 히드로클로라이드의 신규한 다형체 형태
JPH11515030A (ja) シス−ベンズ［ｅ］インドール化合物のエナンチオマー、これらの製造、及びドーパミン−Ｄ３受容体選択的医薬としての利用
JP2001506599A (ja) アルファ−２アドレナリン受容体アゴニストとして有効な２−イミダゾリニルアミノインダゾール化合物
CN108276332A (zh) 一种双阿魏酰胺孪药类化合物及其制备方法和用途
CN106810532A (zh) 一类胺烷氧基噻吨酮类化合物、其制备方法和用途
CN121202835A (zh) 一类胺烷氧基可替宁类化合物及其制备方法和用途
CN114315689A (zh) 二硫烷基邻苯二甲酰亚胺类化合物、其制备方法和用途
JP2023515583A (ja) メチルフェニデートプロドラッグを含む組成物、その作製および使用方法

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P14-X000 Amendment of ip right document requested

St.27 status event code: A-5-5-P10-P14-nap-X000

P16-X000 Ip right document amended

St.27 status event code: A-5-5-P10-P16-nap-X000

Q16-X000 A copy of ip right certificate issued

St.27 status event code: A-4-4-Q10-Q16-nap-X000

PC1903 Unpaid annual fee

Not in force date: 20240413

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240413

St.27 status event code: N-4-6-H10-H13-oth-PC1903